Novo Nordisk -14% after forecasting a 5% to 13% sales drop in 2026 and a 14% Q4 profit decline
Source: [ https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html ](https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html) >Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market. >Eli Lilly was down about 4%, Structure Therapeutics fell 6.2%, while Altimmune dropped 4.2%.